Spinraza / is approved in Canada for patients with type 1 spinal muscular atrophy.
This is the most severe form of SMA.
However, most patients with SMA type II and III are excluded from the treatment
Cure SMA Canada is very happy to announce that the pCPA, provinces and Biogen have FINALLY come to an agreement for the first submission of Nusinersen/Spinraza for review. We are pleased to confirm that all patients with type 1 in all jurisdictions in Canada will be able to access treatment through their public drug plans.
In addition, Biogen is offering coverage of type 2 and 3 patients under an Urgent Access Program. Please see details within their patient community statement through the link below.